10-Q: Lifecore Biomedical Q1 2026 Results Show Revenue Decline

Lifecore Biomedical reported a significant decrease in total revenues for the first quarter of 2026, driven by lower demand in HA manufacturing and CDMO services.

Summary

• Lifecore Biomedical's total revenues for the three months ended March 31, 2026, were $23.19 million, a decrease of 34% compared to $35.15 million in the prior comparable period.
• Cost of goods sold decreased by 26% to $18.73 million.
• Gross profit for the quarter was $4.46 million, a 55% decrease from $9.85 million in the prior period, resulting in a gross profit percentage of 19.2% compared to 28.0%.
• Operating expenses decreased by 52% to $9.13 million, largely due to a significant reduction in R&D expenses and SG&A costs, and the absence of a large loss on asset disposal recorded in the prior period.
• The company reported an operating loss of $4.67 million, an improvement from an operating loss of $9.03 million in the prior comparable period.
• Net loss for the quarter was $14.98 million, compared to a net loss of $14.77 million in the prior period.
• Cash flow from operating activities improved significantly to $4.70 million from $1.20 million in the prior period.
• The company had $20.8 million in cash and cash equivalents as of March 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue and gross profit declines, coupled with a slight increase in net loss, despite improvements in operating cash flow and reduced operating expenses.

Positives

• Operating cash flow significantly improved to $4.70 million from $1.20 million in the prior comparable period.
• Operating loss narrowed to $4.67 million from $9.03 million in the prior comparable period.
• Total operating expenses decreased by 52% to $9.13 million, driven by reductions in R&D and SG&A, and the absence of a large loss on asset disposal.
• The company maintained compliance with all financial covenants under its credit agreements.
• Cash and cash equivalents stood at $20.8 million as of March 31, 2026, with an additional $17.3 million available under the revolving credit facility.

Negatives

• Total revenues decreased by 34% to $23.19 million, primarily due to lower demand in HA manufacturing and CDMO services.
• Gross profit decreased by 55% to $4.46 million, with the gross profit margin declining from 28.0% to 19.2%.
• Net loss increased slightly to $14.98 million from $14.77 million in the prior comparable period.
• The company has significant debt obligations, with approximately $194.2 million in total indebtedness to Alcon.
• The Redeemable Convertible Preferred Stock holders have the right to require redemption starting June 29, 2026, which could require significant cash outlays that the company's internally generated cash is not expected to cover.

Risks

• The timing and amount of future expenses, revenue, cash flow, and capital requirements, and the timing and availability of additional financing.
• Ability to maintain or expand relationships with current customers and the impact of changes in consumer demand.
• Ability to grow and diversify the business with new customers, including the potential loss of development customers.
• Ability to comply with covenants under credit agreements and to pay required interest and principal payments.
• Ability to fund redemptions of Series A Redeemable Convertible Preferred Stock if requested by holders.
• Ability to raise additional capital for ongoing needs.
• Impact of macroeconomic events on operations and financial performance.
• Performance of third-party suppliers.
• Pharmaceutical industry market forces impacting customer success and demand.
• Ability to recruit or retain key scientific, technical, business development, and management personnel.
• Ability to comply with stringent U.S. and foreign government regulations in pharmaceutical product manufacturing.
• Outcome and cost of existing and any new litigation or regulatory proceedings.

Future Outlook

Lifecore expects to further improve efficiencies and productivity through additional procurement and operational strategies, leveraging its new ERP system to strengthen inventory control, financial management, and cost reduction. The company has hired a head of business transformation to drive these efforts. The company expects its current liquidity sources to be sufficient to finance its operational and capital requirements for at least the next twelve months.

Management Comments

• We have improved operations by expanding our revenue-generating capacity, increasing our focus on manufacturing efficiency and cost management, and investing in systems and processes to support more effective execution.
• Through these and other initiatives, the Company believes that it has improved workforce productivity, reflecting the performance-driven culture at Lifecore and underscoring the Company's commitment to continuous improvement.
• We have strengthened our financial position through, among other actions, raising $24.3 million in a private placement of Lifecore common stock in October 2024, a three-year term extension of our existing asset-based lending revolving credit facility with BMO in November 2024, the sale of certain excess capital equipment for $17 million in January 2025, the repayment of $19.7 million of borrowings on our outstanding revolving credit facility over the past 18 months, reduced obligations with the payment of an aggregate amount of $4.7 million to the holders of the Redeemable Convertible Preferred Stock in full satisfaction of outstanding registration delay fees in November 2025, and the implementation of operational cost reductions, including overhead costs and professional fees associated with legal, accounting and consulting spend.

Industry Context

StockSavvy.ai notes that Lifecore Biomedical operates in the highly competitive Contract Development and Manufacturing Organization (CDMO) and pharmaceutical ingredient manufacturing sector. The reported revenue decline, particularly in HA manufacturing, may reflect broader industry trends of supply chain adjustments and shifting customer demand, while the decrease in CDMO revenue could indicate project completion cycles or increased competition in specialized sterile injectable product development and filling.

Comparison to Industry Standards

• The reported gross profit margin of 19.2% is below the typical range for efficient CDMOs, which often aim for margins between 25-40%, depending on specialization and scale.
• The significant increase in operating cash flow is a positive sign, but the overall net loss indicates ongoing challenges in achieving profitability, a common hurdle for companies in the early to mid-stages of scaling complex manufacturing operations.
• The company's reliance on a single major customer (Alcon) for a significant portion of its revenue (39% in Q1 2026) is a common risk factor in the CDMO industry, where customer concentration can lead to revenue volatility.

Legal Proceedings

• A lawsuit filed by 22NW Fund, L.P. against the Company, two former officers, and five former or current directors for alleged material misrepresentations, breaches of contract, and registration delay fees. The court dismissed most claims, but two remain against the Company. The Company intends to vigorously defend itself.
• A putative class action complaint filed on behalf of stockholders alleging false and misleading statements regarding financial results, internal controls, and financial prospects. A settlement agreement in principle has been reached, subject to court approval.
• A lawsuit filed by one of the former owners of Yucatan Foods L.P. for breach of employment agreement, breach of contract, and related claims. The first trial resulted in a net award in the Company's favor, and a second trial for the Company's claims against other defendants is stayed.
• The SEC concluded its investigation concerning the financial statement restatement with no action taken against the Company.

Related Party Transactions

• Alcon Research, LLC is the Company's largest customer and also its largest creditor.
• The Company has a Term Loan Credit Facility with Alcon, with approximately $188.6 million outstanding as of March 31, 2026.
• Alcon purchased equipment for $7.73 million in May 2023, which is being leased back to the Company.
• The Company has a contract liability of $3.999 million related to a prepayment from Alcon, which is being derecognized by delivering goods at a discount.
• Interest expense incurred from Alcon instruments was $6.89 million for the quarter.

Stakeholder Impact

• Shareholders: The significant revenue decline and net loss may negatively impact shareholder value. The potential redemption of preferred stock could also dilute common shareholder equity if not managed effectively.
• Creditors: The company's substantial debt obligations to Alcon and compliance with covenants are critical. The company's ability to service its debt is paramount.
• Employees: The focus on business transformation and cost reduction could lead to restructuring or changes in workforce dynamics.
• Customers: The revenue decline in CDMO and HA manufacturing suggests potential impacts on customer project pipelines and supply chain stability. However, the company's commitment to operational improvements aims to ensure continued service.

Next Steps

• The company plans to continue improving efficiencies and productivity through additional procurement and operational strategies.
• The newly hired head of business transformation will champion efforts to improve cost structure, drive productivity, and gain efficiencies.
• The company will provide calendar-based comparative periods in its reports beginning September 30, 2026.
• The final approval hearing for the class action settlement is scheduled for late July 2026.
• Holders of Redeemable Convertible Preferred Stock have the right to require redemption beginning June 29, 2026.

Key Dates

Recommendation

While the company has improved operating cash flow and narrowed its operating loss, the significant decline in revenue and gross profit, coupled with a slight increase in net loss, presents considerable headwinds. The substantial debt burden and the potential for preferred stock redemptions add further risk. The company's ability to execute its operational improvement plans and secure future financing will be critical. Therefore, a 'hold' recommendation is appropriate pending clearer signs of revenue recovery and improved profitability.

Keywords

Lifecore Biomedical, 10-Q, Quarterly Report, CDMO, Hyaluronic Acid, Revenue, Net Loss, Financial Statements, SEC Filing, Biopharmaceutical Manufacturing